Brokerages Set Senti Biosciences, Inc. (NASDAQ:SNTI) Target Price at $9.00

Senti Biosciences, Inc. (NASDAQ:SNTI) has received a consensus recommendation of “Moderate Buy” from the six analysts that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $9.00.

A number of research firms have issued reports on SNTI. HC Wainwright started coverage on shares of Senti Biosciences in a report on Tuesday, October 14th. They issued a “buy” rating and a $12.00 target price on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Senti Biosciences in a research note on Wednesday, October 8th. Wall Street Zen upgraded shares of Senti Biosciences to a “sell” rating in a research report on Saturday, December 13th. Chardan Capital boosted their price target on Senti Biosciences from $12.00 to $13.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. Finally, Leerink Partners assumed coverage on Senti Biosciences in a research note on Friday, November 21st. They set an “outperform” rating and a $6.00 price target on the stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Armistice Capital LLC purchased a new position in shares of Senti Biosciences during the 2nd quarter worth about $1,883,000. Geode Capital Management LLC raised its stake in Senti Biosciences by 395.6% during the second quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock worth $311,000 after purchasing an additional 117,588 shares during the period. Finally, Citadel Advisors LLC purchased a new position in Senti Biosciences during the third quarter worth approximately $117,000. Institutional investors and hedge funds own 25.70% of the company’s stock.

Senti Biosciences Stock Performance

Senti Biosciences stock opened at $1.12 on Friday. The stock has a fifty day moving average of $1.57 and a two-hundred day moving average of $1.69. The company has a market capitalization of $29.44 million, a price-to-earnings ratio of -0.34 and a beta of 2.13. Senti Biosciences has a fifty-two week low of $1.04 and a fifty-two week high of $5.10.

Senti Biosciences (NASDAQ:SNTI) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.10). On average, analysts forecast that Senti Biosciences will post -14.54 EPS for the current fiscal year.

About Senti Biosciences

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.